Latest Thiazoles Stories
Drug associated with a life-threatening heart abnormality when used with another antiviral medicine SILVER SPRING, Md., Oct. 21 /PRNewswire-USNewswire/ -- The U.S.
TAMPA, Fla., Oct. 21 /PRNewswire/ -- Romark Laboratories, L.C.
TAMPA, Fla., May 4 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C.
TAMPA, Fla., April 15 /PRNewswire/ -- Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C.
NORTHBROOK, Ill. and REINACH, Switzerland, April 1 /PRNewswire/ -- Horizon Therapeutics, Inc. and Nitec Pharma AG, both privately held companies, today announced a definitive agreement in which the two companies have combined in an all-stock transaction.
TAMPA, Fla., Feb. 1 /PRNewswire/ -- Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of AliniaÂ® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.
SCHAUMBURG, Ill., Dec. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of two antibiotics: cefoxitin for injection, USP and ceftriaxone for injection, USP.
Wild birds of several species are dying in large numbers from a paralytic disease with hitherto unknown cause in the Baltic Sea area. A research team at Stockholm University, Sweden
Editorial Accompanies Manuscript in March Issue TAMPA, Fla., March 2 /PRNewswire/ -- A study evaluating nitazoxanide in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV) infection with genotype 4 was published in the March issue of Gastroenterology, the official journal of the American Gastroenterological Association Institute (AGA Institute).
Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co.